Targeting spike glycans to inhibit SARS-CoV2 viral entry
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2301518120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Alex J Guseman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
SARS-CoV-2 spike harbors glycans which function as ligands for lectins. Therefore, it should be possible to exploit lectins to target SARS-CoV-2 and inhibit cellular entry by binding glycans on the spike protein. Burkholderia oklahomensis agglutinin (BOA) is an antiviral lectin that interacts with viral glycoproteins via N-linked high mannose glycans. Here, we show that BOA binds to the spike protein and is a potent inhibitor of SARS-CoV-2 viral entry at nanomolar concentrations. Using a variety of biophysical approaches, we demonstrate that the interaction is avidity driven and that BOA cross-links the spike protein into soluble aggregates. Furthermore, using virus neutralization assays, we demonstrate that BOA effectively inhibits all tested variants of concern as well as SARS-CoV 2003, establishing that multivalent glycan-targeting molecules have the potential to act as pan-coronavirus inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.
- Center for Vaccine Research and Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
ORCID-Profile: Alex J Guseman, Linda J Rennick, Ralph S Baric, Zandrea Ambrose, W Paul Duprex, Angela M Gronenborn
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
- Howard Hughes Medical Institute
- Life Science Research Foundation
- Burroughs Wellcome Fund
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- DSF Charitable Foundation
Zitieren
APA
Guseman, A. J., Rennick, L. J., Nambulli, S., Roy, C. N., Martinez, D. R., Yang, D. T., Bhinderwala, F., Vergara, S., Schaefer, A., Baric, R. S., Ambrose, Z., Duprex, W. P., & Gronenborn, A. M. (2023). Targeting spike glycans to inhibit SARS-CoV2 viral entry. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2301518120
Vancouver
Guseman AJ, Rennick LJ, Nambulli S, Roy CN, Martinez DR, Yang DT, et al. Targeting spike glycans to inhibit SARS-CoV2 viral entry. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2301518120
BibTeX
@article{Guseman2023,
author = {Guseman, Alex J and Rennick, Linda J and Nambulli, Sham and Roy, Chandra N and Martinez, David R and Yang, Darian T and Bhinderwala, Fatema and Vergara, Sandra and Schaefer, Alexandra and Baric, Ralph S and Ambrose, Zandrea and Duprex, W Paul and Gronenborn, Angela M},
title = {Targeting spike glycans to inhibit SARS-CoV2 viral entry},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2301518120}
}
EUVIMED